Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 4/20 | 0.33 |
| ▸ | REN | P00797 | 3/20 | 0.32 |
| ▸ | STS | P08842 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SHBG | P04278 | 1/20 | 0.31 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29613163 | 1.00 | EHMT2 (0.33) | EHMT2RENSTSCYP1A2CYP3A4 | |
| SCHEMBL19270663 | 1.00 | EHMT2 (0.33) | EHMT2RENSTSCYP1A2CYP3A4 | |
| SCHEMBL18426831 | 1.00 | EHMT2 (0.33) | EHMT2RENSTSCYP1A2CYP3A4 | |
| SCHEMBL19273044 | 1.00 | EHMT2 (0.33) | EHMT2RENSTSCYP1A2CYP3A4 | |
| SCHEMBL19270670 | 1.00 | EHMT2 (0.33) | EHMT2RENSTSCYP1A2CYP3A4 | |
| SCHEMBL19273043 | 1.00 | EHMT2 (0.33) | EHMT2RENSTSCYP1A2CYP3A4 | |
| SCHEMBL19252802 | 0.94 | EHMT2 (0.34) | EHMT2REN | |
| SCHEMBL19273152 | 0.88 | HTR2C (0.31) | POLB | |
| SCHEMBL19270687 | 0.88 | HTR2C (0.31) | POLB | |
| SCHEMBL19270688 | 0.88 | HTR2C (0.31) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3998269-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | Novartis AG (CH) | 2022-05-18 | — | — | EP | disclosed |
| EP-3416946-B1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2021-09-15 | — | — | EP | disclosed |
| EP-3615533-B1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2021-09-08 | — | — | EP | disclosed |
| US-20190300530-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2019-10-03 | — | — | US | disclosed |
| US-10301312-B2 | Fused indazole pyridone compounds as antivirals | NOVARTIS AG (CH) | 2019-05-28 | — | — | US | disclosed |
| US-9845325-B2 | Tetracyclic pyridone compounds as antivirals | NOVARTIS AG (CH) | 2017-12-19 | — | — | US | disclosed |
| WO-2017140821-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300530-A1 | FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS | CYP3A5, CYP3A43, CYP3A4 | EHMT2 4311/4885REN 1821/4885STS 3419/4885 |
| US-10301312-B2 | Fused indazole pyridone compounds as antivirals | CYP3A5, CYP3A43, CYP3A4 | EHMT2 4311/4885REN 1821/4885STS 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.